AIM ImmunoTech (NYSE American: AIM) Sparks Debate After Reverse Split Proposal Amid Delisting Risk
Can This Controversial Biotech Stock Bounce Back or Is It Game Over?
AIM ImmunoTech Inc. (NYSE American: AIM), a clinical-stage biopharmaceutical company focused on immunomodulatory therapies, has ignited heated discussions among retail investors after revealing plans for a potential reverse stock split. The move comes as the company faces a delisting notice from the NYSE American exchange due to its share price remaining below the $1.00 threshold for an extended period.
The reverse stock split proposal, aimed at bringing AIM’s share price back into compliance, has generated both optimism and skepticism in online trading communities. While some investors believe this could pave the way for institutional interest and greater long-term viability, others fear it may simply mask deeper financial issues and precede further dilution.
AIM’s lead product candidate, Ampligen, is being studied for multiple indications, including certain cancers and viral infections such as COVID-19 and ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome). Despite ongoing clinical trials and some encouraging data, the stock has remained volatile, recently trading below $0.30 — a level that has alarmed many shareholders.
Investors are concerned about dilution following the potential reverse split, especially given AIM’s history of capital raises through share offerings. Additionally, frustrations have been mounting around management transparency and the pace of clinical development, with some long-term holders questioning the company’s strategic direction.
Still, a subset of retail traders remains bullish. They argue that if AIM successfully executes the reverse split and maintains its listing, the stock could become more attractive to institutional investors who are typically restricted from trading sub-dollar stocks. This increased exposure could, in theory, provide fresh momentum to a stock that’s been treading water for months.
Adding to the uncertainty is rampant speculation around potential partnerships or licensing deals involving Ampligen. While management has hinted at ongoing discussions, no concrete updates have been provided — leaving many investors in limbo and feeding into the stock’s wild price swings.
With the shareholder meeting scheduled in the coming weeks to vote on the reverse split proposal, the outcome could determine AIM’s short-term fate. For now, the ticker AIM continues to trend as traders weigh the risks of delisting against the potential upside of a strategic reset.